NO20044568L - Fremgangsmate for inhibering av atrofi eller for behandling eller forhindring av atrofi-relaterte symptomer i kvinner - Google Patents

Fremgangsmate for inhibering av atrofi eller for behandling eller forhindring av atrofi-relaterte symptomer i kvinner

Info

Publication number
NO20044568L
NO20044568L NO20044568A NO20044568A NO20044568L NO 20044568 L NO20044568 L NO 20044568L NO 20044568 A NO20044568 A NO 20044568A NO 20044568 A NO20044568 A NO 20044568A NO 20044568 L NO20044568 L NO 20044568L
Authority
NO
Norway
Prior art keywords
atrophy
women
inhibition
prevention
procedure
Prior art date
Application number
NO20044568A
Other languages
English (en)
Other versions
NO334090B1 (no
Inventor
Pirkko Harkonen
Kaija Halonen
Taru Blom
Paula Gronroos
Original Assignee
Hormos Medical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hormos Medical Corp filed Critical Hormos Medical Corp
Publication of NO20044568L publication Critical patent/NO20044568L/no
Publication of NO334090B1 publication Critical patent/NO334090B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Medicinal Preparation (AREA)

Abstract

Det beskrives en fremgangsmåte for hemning av hudatrofi eller epitelial eller mukosal atrofi hos kvinner eller en fremgangsmåte for behandling eller forebygging av symptomer beslektet med nevnte atrofi, nevnte fremgangsmåte omfatter administrering til kvinnen av en effektiv mengde av forbindelsen med formel (I) eller en geometrisk isomer, en stereoisomer, et farmasøytisk akseptabelt salt, en ester derav eller en metabolitt derav.
NO20044568A 2002-06-06 2004-10-22 Anvendelse av toremifenforbindelser for fremstilling av en farmasøytisk sammensetning for hemming av urogenital atrofi hos kvinner NO334090B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38590402P 2002-06-06 2002-06-06
PCT/FI2003/000369 WO2003103649A1 (en) 2002-06-06 2003-05-14 Method for the inhibition of atrophy or for treatment or prevention of atrophy-related symptoms in women

Publications (2)

Publication Number Publication Date
NO20044568L true NO20044568L (no) 2004-12-22
NO334090B1 NO334090B1 (no) 2013-12-09

Family

ID=29736123

Family Applications (3)

Application Number Title Priority Date Filing Date
NO20044568A NO334090B1 (no) 2002-06-06 2004-10-22 Anvendelse av toremifenforbindelser for fremstilling av en farmasøytisk sammensetning for hemming av urogenital atrofi hos kvinner
NO20131189A NO336612B1 (no) 2002-06-06 2013-09-04 Anvendelse av en forbindelse for fremstilling av en farmasøytisk sammensetning for hemming av urininkontinens i en kvinne
NO20150487A NO339194B1 (no) 2002-06-06 2015-04-22 Anvendelse av en forbindelse for fremstilling av en farmasøytisk sammensetning for hemming av urinveisinfeksjon hos en kvinne

Family Applications After (2)

Application Number Title Priority Date Filing Date
NO20131189A NO336612B1 (no) 2002-06-06 2013-09-04 Anvendelse av en forbindelse for fremstilling av en farmasøytisk sammensetning for hemming av urininkontinens i en kvinne
NO20150487A NO339194B1 (no) 2002-06-06 2015-04-22 Anvendelse av en forbindelse for fremstilling av en farmasøytisk sammensetning for hemming av urinveisinfeksjon hos en kvinne

Country Status (24)

Country Link
EP (1) EP1509215B1 (no)
JP (1) JP4362442B2 (no)
KR (1) KR100991157B1 (no)
CN (2) CN101406464A (no)
AT (1) ATE344025T1 (no)
AU (1) AU2003227790B2 (no)
BR (1) BR0311613A (no)
CA (1) CA2484542C (no)
CY (1) CY1105787T1 (no)
DE (1) DE60309465T2 (no)
DK (1) DK1509215T3 (no)
ES (1) ES2270025T3 (no)
HR (1) HRP20041150B1 (no)
IL (1) IL164528A (no)
MX (1) MXPA04012220A (no)
NO (3) NO334090B1 (no)
NZ (1) NZ536118A (no)
PL (1) PL214242B1 (no)
PT (1) PT1509215E (no)
RU (1) RU2317816C2 (no)
SI (1) SI1509215T1 (no)
UA (1) UA79797C2 (no)
WO (1) WO2003103649A1 (no)
ZA (1) ZA200408321B (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8236861B2 (en) * 2004-02-13 2012-08-07 Hormos Medical Corporation Method for enhancing the bioavailablity of ospemifene
US8642079B2 (en) 2004-02-23 2014-02-04 Hormos Medical Corporation Solid formulations of ospemifene
CN1950071A (zh) 2004-05-04 2007-04-18 霍尔莫斯医疗有限公司 ospemifene的新口服制剂
US8758821B2 (en) 2004-05-04 2014-06-24 Hormos Medical Ltd. Oral formulations of ospemifene
JP5193196B2 (ja) 2006-06-02 2013-05-08 ペア ツリー ウーマンズ ヘルス ケア 萎縮性膣炎の治療の方法
SI2121553T1 (sl) 2007-02-14 2012-11-30 Hormos Medical Ltd Postopek za pripravo terapevtsko uporabnih trifenilbutenskih derivatov
WO2008099060A2 (en) 2007-02-14 2008-08-21 Hormos Medical Ltd Methods for the preparation of fispemifene from ospemifene
US9321712B2 (en) 2012-10-19 2016-04-26 Fermion Oy Process for the preparation of ospemifene
KR102052133B1 (ko) 2017-08-10 2019-12-05 고려대학교 산학협력단 당 부가된 오스페미펜, 이의 제조방법 및 이를 유효성분으로 함유하는 약학적 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5352699A (en) * 1992-04-30 1994-10-04 University Of Massachusetts Medical Center Use of retinioc acid to treat vaginal atrophy
US5461064A (en) * 1993-12-21 1995-10-24 Eli Lilly And Company Methods of inhibiting atrophy of the skin and vagina
US5747059A (en) * 1996-01-11 1998-05-05 Novo Nordisk A/S Atrophy of skin/mucous membrane
RU2342145C2 (ru) * 2000-01-28 2008-12-27 Андорешерш, Инк. Селективные модуляторы рецептора эстрогена в комбинации с эстрогенами
US20010034340A1 (en) * 2000-03-20 2001-10-25 American Home Products Corporation Hormone replacement therapy
US6245819B1 (en) * 2000-07-21 2001-06-12 Hormos Medical Oy, Ltd. Method for the treatment of vaginal dryness and sexual dysfunction in women during or after the menopause

Also Published As

Publication number Publication date
IL164528A (en) 2010-06-30
RU2317816C2 (ru) 2008-02-27
CN100448437C (zh) 2009-01-07
NO336612B1 (no) 2015-10-12
HRP20041150A2 (en) 2006-03-31
AU2003227790B2 (en) 2007-11-29
BR0311613A (pt) 2005-03-08
RU2004138571A (ru) 2005-06-10
KR20050004292A (ko) 2005-01-12
DE60309465T2 (de) 2007-08-30
JP2005532353A (ja) 2005-10-27
MXPA04012220A (es) 2005-04-08
ZA200408321B (en) 2006-07-26
PL214242B1 (pl) 2013-07-31
CN1658851A (zh) 2005-08-24
NZ536118A (en) 2007-08-31
CA2484542C (en) 2010-11-02
WO2003103649A1 (en) 2003-12-18
KR100991157B1 (ko) 2010-11-02
HRP20041150B1 (en) 2007-06-30
JP4362442B2 (ja) 2009-11-11
CN101406464A (zh) 2009-04-15
NO339194B1 (no) 2016-11-14
AU2003227790A1 (en) 2003-12-22
CY1105787T1 (el) 2011-02-02
EP1509215A1 (en) 2005-03-02
IL164528A0 (en) 2005-12-18
EP1509215B1 (en) 2006-11-02
CA2484542A1 (en) 2003-12-18
DE60309465D1 (de) 2006-12-14
ATE344025T1 (de) 2006-11-15
NO20150487L (no) 2004-12-22
SI1509215T1 (sl) 2007-02-28
NO20131189L (no) 2004-12-22
DK1509215T3 (da) 2007-03-12
NO334090B1 (no) 2013-12-09
PL372758A1 (en) 2005-08-08
UA79797C2 (en) 2007-07-25
ES2270025T3 (es) 2007-04-01
PT1509215E (pt) 2007-01-31

Similar Documents

Publication Publication Date Title
EE200300031A (et) Klimakteersete häirete ravimeetod naistel menopausi ajal või järel
TW200420549A (en) Thiazole derivatives
WO2001081312A3 (en) Method of treatment using phenyl and biaryl derivatives as prostaglandin e inhibitors and compounds useful therefore
ATE539749T1 (de) Dextromethorphan für die behandlung von akne
NO20044568L (no) Fremgangsmate for inhibering av atrofi eller for behandling eller forhindring av atrofi-relaterte symptomer i kvinner
IS7315A (is) Útskipt díketópíperasín sem oxýtósínmótlyf
IL159241A0 (en) Use of branched-chain fatty acids and derivatives thereof for the treatment of pain
NO20061999L (no) Anvendelse av syliske anabaenopeptin-type peptider for behandling av en tilstand hvor inhibering av karboksypeptidase U er fordelaktig, nye anabaenopeptin-derivater og mellomprodukter derav
RU2008143055A (ru) Ингибиторы ренина, предназначенные для гипертензии
DE60004996D1 (de) Aminotetralin derivate zur therapie der kardiovaskulären erkrankungen
HK1080768A1 (en) Use of epothilone derivatives for the treatment ofhyperparathyroidism
WO2004064761A3 (en) Therapeutically active compounds
IL136717A (en) Carboxylic acid substituted heterocycles as metalloproteinase inhibitors

Legal Events

Date Code Title Description
MK1K Patent expired